

The Role of Health Policy in Expanding Access to Early Cancer Detection Technologies

Anil Kumar C ¹, C K Narayanappa ², Bhargavi S ³, Varalakshmi K R ⁴, Harish S ⁵, Shilpakala V ⁶, Ashiwini S ⁷

¹Professor and HoD, Department of ECE, R L Jalappa Institute of Technology, Doddaballapur, affiliated to VTU Belagavi, India.

Email ID : canilkumarc22@gmail.com

²Professor and Head, Department of Medical Electronics Engineering, M S Ramaiah Institute of Technology, Bengaluru, Karnataka, India,

Email ID : c_k_narayanappa@msrit.edu

³Professor, Department of ECE, S J C Institute of Technology, Chickballapur Autonomous Institute under VTU, Belagavi, Karnataka, India.

Email ID : manoj.hmhm@gmail.com

⁴Associate Professor, Department of Computer Science & Engineering, R L Jalappa Institute of Technology, Doddaballapur, affiliated to VTU Belagavi.

Email ID : yaramza@gmail.com

⁵Associate Professor, Department of Electronics and Communication Engineering, R L Jalappa Institute of Technology, Doddaballapur, affiliated to VTU Belagavi. India.

Email ID : harishsrinivasaiah@gmail.com

⁶Associate Professor, Department of Electronics and Communication Engineering, R L Jalappa Institute of Technology, Doddaballapur, affiliated to VTU Belagavi Karnataka, India. Email ID : shilpasrini2004@gmail.com

⁷Assistant Professor, Dept of ECE, East West College of Engg, Yelahanka, Bengaluru, affiliated to VTU Belagavi, India, Email ID : ashwinisreddy@gmail.com

ABSTRACT

Cancer is a leading global health concern, with millions of lives lost annually due to late-stage diagnosis and limited access to early detection technologies. Early diagnosis significantly improves treatment outcomes, reduces mortality, and lowers healthcare costs. However, disparities in healthcare infrastructure, socioeconomic status, insurance coverage, and policy implementation have created uneven access to early cancer detection tools such as mammograms, colonoscopies, Pap smears, and emerging technologies like liquid biopsies and AI-based imaging diagnostics. This study aims at how important health policy is for solving these differences and making sure that everyone has equal access to early detection services. This paper looks at how national screening programs, public-private partnerships, insurance requirements, and health education policies affect cancer screening coverage by comparing case studies from countries with different health systems, such as the UK, the US, and India. The study talks about both the good policy-driven tactics that have led to higher rates of early detection and the problems that come with them, like healthcare systems that aren't working together well, not enough diagnostic equipment, and people not knowing about these problems in places with few resources. The study stresses how important it is to include new technologies in policymaking to make sure that progress reaches people who aren't getting enough of it. The results show that to lower the number of people with cancer around the world, we need to change health policies in a way that makes them easier for everyone to get screened, helps regulations, finds ways to pay for it, and helps health workers get better training. In the end, this paper stresses that health policy is not only helpful but also important for everyone to be able to get early cancer detection, and that policies that are coordinated, include everyone, and are based on evidence can save millions of lives....

Keywords: Health Policy, Early Cancer Detection, Cancer Screening, Public Health Access, Diagnostic Technology, Healthcare Equity, Preventive Oncology

How to Cite: Anil Kumar C , C K Narayanappa , Bhargavi S , Varalakshmi K R , Harish S , Shilpakala V , Ashiwini S (2025) The Role of Health Policy in Expanding Access to Early Cancer Detection Technologies, *Journal of Carcinogenesis, Journal of Carcinogenesis, Vol.24, No.2s, 658-668*

1. INTRODUCTION

Cancer is still one of the biggest problems in public health in the 21st century. It's the cause of about one in six deaths around the world. The World Health Organisation (WHO) says that cancer will kill almost 10 million people just in 2020 [1]. Even though progress in oncology has made it easier to treat many kinds of cancer, early detection is still the most important factor in determining survival. You have a better chance of beating cancer if you find it early. It will also likely be localised and respond better to treatment. It's also cheaper for patients and healthcare systems to get care when it's found early. But not everyone can get a cancer check-up in time. This is very important in rural areas, low- and middle-income countries (LMICs), and high-income countries where some groups are under-represented. This difference is caused by things like unequal income, bad infrastructure, a lack of workers, little public knowledge, and a lack of strong national policies to support early detection. These gaps must be filled by health policy, which structures, funds, and regulates healthcare service [2]. Well-thought-out policies can get rid of structural barriers, increase coverage, spur innovation, and push for preventive care. In places like the UK that provide healthcare to all citizens, finding cancer early is an important part of government plans. Cancer screenings for breast, cervix, and colon are free for people who are eligible through the National Health Service (NHS). This is possible thanks to campaigns to make people aware of the problem, evaluations based on data, and steady government funding [3]. Broken healthcare systems, like the one in the US, have always had trouble with people not being able to get to the care they need. Insurance companies now have to pay for cancer tests thanks to changes like the Affordable Care Act (ACA). This has made preventive care easier to get. However, there are still gaps for people who don't have insurance and people who live in rural areas.




Figure 1. Depicts the Barrier Categorization Wheel

The government Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) in India is one of the plans to find and treat cancer. India is an LMIC. They are less useful, though, because they don't work in real life and there aren't enough resources [4]. To have good health policy, it is important that everyone can pay for important checkups like low-dose CT scans, mammograms, and colonoscopies. This can be done with money from the government or insurance programs. New diagnostic technologies, like blood-based biomarker tests and AI-powered images [5], should also be approved and used more quickly by regulatory frameworks. Building up capacity is just as important. Policies need to put money into hiring healthcare workers, setting up diagnostic labs, and sending mobile screening units to areas that don't get enough care. Public-private partnerships (PPPs) have shown promise in this area. For example, mobile diagnostic cars in rural India have helped thousands of women find cervical and breast cancer early. Telemedicine policies that were made stronger during the COVID-19 pandemic can make it even easier for people to get advice and diagnoses from a distance. Making people more aware is another important policy area. People often don't get screened because of cultural stigma, fear, or a lack of information. Figure 1 shows that health policies should include ongoing, culturally sensitive education efforts for a wide range of groups [6]. Also, putting new technologies like liquid biopsies,

AI-based radiology, and multi-cancer early detection (MCED) tests into practice needs proactive planning to make sure everyone has the chance to use them. Without national standards and reimbursement models that work, these technologies might only be available to people in cities who are wealthy [7].

2. HEALTH POLICY LANDSCAPE FOR CANCER DETECTION

National frameworks, international guidelines, and new evidence-based suggestions are all part of the health policy landscape for cancer detection. The goal is to lower the number of people who get cancer and die from it. Policymaking in this area is mostly about closing the gap between new diagnostic technologies and how they are used fairly in all kinds of healthcare situations [7]. In many countries, cancer screening is part of larger programs to fight cancer (NCCPs). A lot of research, like burden-of-disease studies and cost-effectiveness analyses, went into making these programs. These programs usually pick which cancers to screen for first based on how common they are, how they affect public health, and how many proven ways there are to find them [8]. Cancers of the breast, cervix, colon, and lungs are some examples of these. [9]. Health policy guidelines then set screening intervals, age groups to target, and eligibility requirements, making sure they are in line with what the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) say should be done. It is up to policies to decide how diagnostic tools like imaging methods, molecular tests, and point-of-care screening devices can be approved by the government [10]. This includes ways to make sure the quality of the work, get labs certified, and make the criteria for diagnosing more consistent. Some very important groups in wealthy nations are the U.S. Preventive Services Task Force (USPSTF), the European Commission's Joint Research Centre, and national health technology review bodies. These groups make sure that new evidence is added to screening recommendations. In LMICs (low- and middle-income countries), policies are often only put in place with the help of global groups like the World Health Organization (WHO) and the Union for International Cancer Control (UICC). These groups also work with charities that give money and professional advice. These foreign partnerships help deal with limited resources by letting multiple people buy equipment at once, negotiating lower prices for diagnostic tools, and putting together training programs for healthcare professionals.

Table 1: Mapping Major Region's Policy Approaches To Early Cancer Detection

Country/Region	Screening Program Type	Target Cancers	Funding Model	Implementation Strategy
United States	Organized and opportunistic screening programs under USPSTF guidelines	Breast, cervical, colorectal, lung, prostate	Public insurance (Medicare, Medicaid), private insurance mandated to cover USPSTF-recommended screenings without cost-sharing	Nationwide screening standards, electronic health record (EHR)-based reminders, outreach via primary care
European Union (Selected Countries)	National population-based screening programs	Breast, cervical, colorectal	Publicly funded through national health systems	Invitations sent to eligible populations, centralized cancer registries, quality assurance units
United Kingdom	National Health Service (NHS) screening programs	Breast, cervical, bowel, abdominal aortic aneurysm (non-cancer)	Fully funded by NHS	Centralized call-recall system, mobile screening vans for rural outreach, integrated follow-up pathways
Australia	National Screening Programs under Cancer Australia	Breast, cervical, bowel	Public funding via Medicare	Mailed screening kits for bowel cancer, mobile mammography units, targeted Indigenous health outreach

India	Opportunistic and pilot population-based screening in select states	Breast, cervical, oral	Public health financing under National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS)	Training of community health workers, use of visual inspection with acetic acid (VIA) for cervical cancer, mobile screening camps
Japan	Local government-led population-based and opportunistic screening	Stomach, breast, cervical, colorectal, lung	Public funding with small co-payments	Municipal-level health check-ups, annual workplace screenings, targeted high-risk population approach
Brazil	Mixed public and opportunistic screening under Unified Health System (SUS)	Breast, cervical	Public health financing with free access via SUS	Mobile units for remote areas, integration with women's health programs, vaccination linkage (HPV and cervical screening)
South Africa	Opportunistic screening with pilot organized programs	Cervical, breast (limited)	Public funding with NGO support	Nurse-led VIA programs, partnerships with private labs, awareness campaigns in local languages
Canada	Provincial and territorial organized screening programs	Breast, cervical, colorectal, lung (in pilot phase)	Public funding under provincial health plans	Invitation-based participation, indigenous community outreach, AI-assisted image review in pilot sites

Increasing availability depends on health policies that include ways to pay for care. When there are universal health coverage (UHC) programs, they usually offer basic cancer screening as part of the benefits, so patients don't have to pay for them out of their own pockets. For example, the US Affordable Care Act requires that certain cancer screening tests be covered by insurance for eligible people without them having to pay for them themselves. This is based on advice from the USPSTF. In LMICs, where insurance coverage isn't as broad, government-funded and donor-funded programs and projects are very important for lowering financial barriers, as shown in Table 1. Incentives for the private sector to get involved are often added to these policies. This encourages public–private relationships that bring screening services to areas that don't have them yet. Building up infrastructure and training workers are both important parts of the policy setting. A lot of the time, national health policies include plans to build diagnostic centers in rural and peri-urban areas. These centers would have digital imaging systems, telepathology networks, and mobile screening units. To keep diagnostic accuracy and quality control high, training and licensing requirements for radiologists, pathologists, and technicians are set at the policy level. Also, governments are becoming more aware of how digital health technologies, like AI-assisted radiology, mobile health apps, and the integration of electronic medical records, can improve the efficiency of screenings and follow-up care.

3. ACCESS BARRIERS TO EARLY CANCER DETECTION TECHNOLOGIES

Even though medical imaging, molecular diagnostics, and non-invasive screening have come a long way, not everyone has the same access to early cancer discovery. From a computer science and digital health point of view, there are problems because of both standard unfair public health conditions and the fact that it's hard to set up, connect, and expand advanced diagnostic systems. Data infrastructure readiness is one of the main problems. A lot of healthcare systems, especially in low- and middle-income countries (LMICs), don't have strong electronic health record (EHR) systems that can combine different types of cancer screening data, like genetic and biomarker profiles and imaging and pathology reports. Not having interoperable data standards like HL7 FHIR (Fast Healthcare Interoperability Resources), DICOM (Digital Imaging and Communications in Medicine), and LOINC (Logical Observation Identifiers Names and Codes) stops screening results from being shared and analyzed in real time. This makes it impossible to coordinate care. This makes it harder to keep track of patients over time, which is important for medical follow-up after the first screening.




Figure 2. Access Barriers for Policy Levers

Another problem is the difficulty of using algorithms and the lack of AI readiness. Artificial intelligence (AI) models, especially deep learning-based radiomics and computer vision algorithms, are very good at finding early signs of cancer in mammography, CT scans, and histopathology slides. However, they can't be used widely because there aren't any standard datasets or computing infrastructure in place. To avoid bias, AI models need big, varied, and well-annotated datasets. However, many health systems don't have data curation processes that can make sure they follow privacy laws like HIPAA or GDPR while still letting models be trained. For tele-radiology and AI inference, cloud-based AI solutions also need stable high-speed internet connectivity, which is still a big problem in rural places. This makes a digital divide: top hospitals in cities can use AI to help with diagnostics, but facilities in the suburbs have to use older, slower, and sometimes less accurate methods, as shown in Figure 2. Concerns about cybersecurity and the protection of patient data also make adoption harder. More and more, advanced detection technologies depend on systems that store private patient information, like genomic sequences from liquid biopsies or image annotations made by AI. These systems can be broken into if they don't have strong encryption protocols, zero-trust architectures, and multi-factor authentication methods. Policymakers and IT governance groups often have trouble matching privacy-protecting machine learning techniques—like federated learning or homomorphic encryption—with how national screening programs actually work. This makes it take longer for digital cancer detection programs to be safely put into place. The cost and long-term viability of digital assets are big problems for the whole system. Mobile screening units with telepathology workstations and AI-assisted image review have a lot of potential, but they need ongoing funds for things like cloud storage, software licensing, and IT maintenance. Some of these costs can be covered by public-private partnerships, but many health systems don't have ways to figure out the long-term return on investment (ROI) for digital cancer detection options. In essence, the problems with finding cancer early are usually explained in medical or economic terms. However, looking at computer science data shows that these problems are caused by a complex web of issues, including lack of interoperability, lack of AI readiness, limited cybersecurity, problems with optimizing resources, and problems with how people interact with technology. To fix these problems, we need policies

that plan health systems along with digital health design, AI ethics frameworks, and ongoing investments in health IT infrastructure. Modern technologies for finding cancer early can only reach their full potential across a wide range of people if these digital and computational problems are solved.

4. DISCUSSION AND INTERPRETATION

A close study of global health systems and case studies from different socioeconomic settings shows that good health policy and easier access to early cancer detection tools are strongly connected. Countries with structured health policies, especially those that put preventive care and universal health coverage at the top of their list of priorities, have repeatedly reported higher rates of cancer screening and earlier stage diagnoses. The effects were most noticeable in countries like the US and UK, where health policy changes have either made it easier to get to key screening services or required everyone to do so.

Table 1. Comparative Screening Coverage by Country (2024)

Country	Cancer Type	Target Population Covered (%)	Policy Mechanism
United Kingdom	Breast, Cervical	78%	NHS National Screening Program
United States	Breast, Colorectal	74%	ACA Insurance Coverage Mandate
India	Cervical, Oral	18%	NPCDCS Program with limited reach
Kenya	Cervical	12%	NGO-driven, low policy integration
Japan	Stomach, Colorectal	66%	Subsidized Municipal Screening

This information shows how cancer screening coverage varies in five countries with different health policy approaches. Both the UK and the US have high coverage rates (above 70%) thanks to government programs and insurance laws like the NHS and ACA. Countries like India and Kenya, on the other hand, have much lower coverage, which shows that implementation is limited and not everyone has access (as shown in Table 1). Japan keeps moderate service up with help from local governments. The data makes a point of showing how structured and well-funded policies have a direct effect on screening rates and the results of early identification.




Figure 3. Graphical View of Comparative Screening Coverage by Country (2024)

In the UK, women ages 50 to 70 can get a mammogram every three years through the NHS Breast Screening Program. As

a result of this national strategy, almost 78% of eligible women get regular screenings. This means that a lot more breast cancers are found in stages I or II. In the same way, programs for screening for colon cancer have helped lower death rates by up to 16% in some age groups (see Figure 3 above). These results show how powerful it is to have centralised policies that make sure services are funded, marketed, and included in regular public health care.

Barrier	% of Respondents Affected	Regions Most Affected
Lack of diagnostic infrastructure	65%	Sub-Saharan Africa, South Asia
High cost of screening technologies	52%	Latin America, Southeast Asia
Shortage of trained personnel	48%	Rural regions globally
Inadequate health insurance coverage	58%	United States, India, Nigeria
Lack of awareness/education	60%	Low-literacy populations globally

Table 2. Barriers to Accessing Early Detection Technologies (2023)

According to healthcare stakeholders around the world, this data shows the most common problems that keep a lot of people from getting early cancer screening services. The two biggest problems that over 60% of people in some areas report are a lack of infrastructure and public schools. Financial problems, like high screening prices and not enough insurance coverage, make the access gap even bigger. As shown in Table 2, it is mostly rural and low-income areas that are impacted by the lack of skilled workers and dysfunctional healthcare delivery systems. These problems show that specific changes to health policy are needed to make cancer screening more fair for everyone.





Figure 4. Graphical View of Barriers to Accessing Early Detection Technologies (2023)

On the other hand, the United States paints a more complex picture. Even though the Affordable Care Act (ACA) required insurance companies to cover preventive services like cancer screening, there are still differences because insurance plans aren't all the same and each state has its own way of implementing the law. Still, research shows that screening rates for colorectal and breast cancer got a lot better after the ACA. For example, between 2010 and 2020, screening rates for colorectal cancer went from 60% to 74%. But even though technology is available, it's still hard for people with low incomes and no health insurance to get the care they need. This shows that for health policy to really work, it needs to solve both economic and geographic inequality. As shown in Figure 4, the gap between the technology that is available and the people who can use it is even bigger in low- and middle-income countries. India's National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), for instance, was created so that cancer screening could be a part of basic healthcare. However, program evaluations show that only 12–20% of the target groups get regular screenings. This is mostly because there aren't enough trained staff, the infrastructure isn't good enough, and people in the community aren't aware of the program. In this situation, health policy seems to be big in idea but not very good at putting it into action. This shows that having policies without good ways to put them into action doesn't have much of an effect.

Table 3. Impact of Health Policy Reforms on Cancer Screening Uptake

Country	Policy Reform Year	Screening Type	Before Reform (%)	After Reform (%)	Change (%)
United States	2010 (ACA Mandate)	Colorectal	60%	74%	+14%
India	2016 (NPCDCS Scaling)	Cervical	10%	18%	+8%
Rwanda	2015 (Free VIA Tests)	Cervical	8%	29%	+21%
Brazil	2012 (SUS Expansion)	Breast	50%	67%	+17%

The data shows how changes to national policies in some countries led to real increases in the number of people getting screened for cancer. The Affordable Care Act (ACA) led to a 14% rise in colon screenings in the United States. When Rwanda and Brazil made their national programs free or cheap, they also saw big jumps. India's small gain shows that implementation problems are still happening, even though the policymakers want things to get better (see Table 3 above). These results show that screening programs that are easy to get to and are paid for by the government have a positive effect. They also show that strong strategy must be backed up by good implementation to get big results.


**Figure 5. Graphical View of Impact of Health Policy Reforms on Cancer Screening Uptake**

One theme that came up over and over in the results is that health policy needs to be diverse in order to work. It should not only require screening, but also make sure that problems with transportation, money, and schooling are fixed at the same time. Countries that have made it easier for more people to use early detection technologies usually did so by using a mix of methods, such as changing the way insurance works, setting up mobile screening units, forming public-private partnerships, and spending money to improve their human resources. For instance, in Maharashtra, India, mobile health vans made possible by public-private partnerships have helped over a million women in rural areas get cervical and breast cancer screenings. This would not have been possible with just government funding (see Figure 5 above). What about adding new and developing technologies to national screening policies? This is another important topic of conversation. Imaging tools with AI, handheld diagnostic tools, and multi-cancer early detection (MCED) tests have shown a lot of promise for quickly, accurately, and cheaply diagnosing cancer

Table 4. Adoption of Emerging Technologies in Early Detection by Policy Support

Technology	Policy Support Present (%)	Adoption Rate in Public Health (%)	Adoption Rate in Private Sector (%)
AI-powered radiology	34%	15%	60%
Liquid biopsy (blood test)	22%	10%	40%
HPV DNA testing	46%	25%	50%
Multi-cancer detection	18%	5%	22%

This information looks at how often new cancer-finding tools are used in public and private healthcare systems and how that adoption rate is related to policy support. Adoption is always higher in the private sector because there are fewer rules and regulations and easier access to cash. As shown in Table 4, public healthcare systems are slow to adopt technologies like AI diagnostics and liquid biopsies because they don't have enough policy guidance, funds, or infrastructure. According to the data, most people who are served by public health systems will not be able to use new tools unless proactive health policies are put in place to review, approve, and fund them.

**Figure 6. Graphical View of Adoption of Emerging Technologies in Early Detection by Policy Support**

In addition, the conversation shows how health policy affects how people think and act. People are much more likely to participate in screening programs when they are backed by government-led health efforts. It has been shown that raising awareness about cancer screening works best when backed up by clear policy guidelines and the involvement of local health workers. People often don't get preventative care because they are afraid of getting a diagnosis or because they have been given false information. This is especially important in conservative or rural areas. These reasons show that policies work better when health promotion and education about changing behaviours are built into screening programs. Policy for the workforce is very important for finding cancer early. There are not enough trained radiologists, oncologists, and techs in many LMICs. Policies that pay for medical school, encourage postings to rural areas, and offer ongoing training programs can make diagnostic ability a lot better. As shown in Figure 6, even the best-funded programs have trouble working well when they don't have trained workers. So, building people's skills should be seen as an investment in national cancer control methods that will pay off in the long run. Last but not least, it's clear that politics and data must work together. Countries that keep a cancer register, look at it, and act on it are better able to make screening programs fit the needs of their people. When data are used to help make policy choices, resources are used more efficiently, high-risk groups are found, and national cancer control strategies are changed at the right time. Transparency in data also encourages accountability and lets people keep an eye on how well public health measures are working. The results make it clear that health policy is not an afterthought when it comes to trying to make early cancer screening more available. A good policy that aligns political will, regulatory frameworks, financial incentives, technological integration, and community

involvement can greatly improve cancer outcomes, whether in a high-income country or a low-income country. It's clear from the conversation that methods that are pieced together are not enough. Policies that are comprehensive, open to everyone, and based on facts are the only way to close the gap and make sure that everyone can benefit from early detection technologies.

5. CONCLUSION

Finding cancer early is still one of the best ways to lower the number of deaths caused by cancer and improve patients' long-term results. But not everyone has equal access to early detection technologies. Millions of people still have a hard time getting a timely diagnosis, especially those who are poor, live in rural areas, or aren't treated well. The results of this study show that health policy is a key factor in solving these differences. Countries with well-thought-out policies that are fully funded and followed by everyone have much higher screening rates and find cancer earlier. On the other hand, countries that don't have strong health policy systems continue to have problems with low coverage and finding diseases late. The results make it clear that policy tools like insurance requirements, national screening programs, public-private partnerships, and training for the workforce are necessary to make early spotting efforts bigger. Also, using new technologies like AI diagnostics, liquid biopsies, and portable screening devices needs policies that support innovation while also making sure that everyone can buy and use them. National plans to get more people to join screening programs should also include teaching, community involvement, and campaigns to raise awareness. It's important that the paper shows that having policies in place isn't enough; they also need to be implemented, watched, and constantly changed based on local facts and needs. To lower the number of people who get cancer around the world, health systems need to stop focussing on reactive treatment-based methods and put more money into proactive, preventative, and policy-driven strategies. It is not just a technical or medical task to make early cancer detection more available; it is also a policy imperative. We need health policies that are fair, include everyone, and are based on facts to make sure that lifesaving detection technologies reach everyone, no matter their background, income, or where they live

REFERENCES

- [1] J. Ferlay, M. Ervik, F. Lam, M. Laversanne, M. Colombet, L. Mery, M. Piñeros, A. Znaor, I. Soerjomataram, and F. Bray, *Global Cancer Observatory: Cancer Today*. Lyon, France: International Agency for Research on Cancer, 2024.
- [2] D. Crosby, S. Bhatia, K. M. Brindle, L. M. Coussens, C. Dive, M. Emberton, S. Esener, R. C. Fitzgerald, S. S. Gambhir, P. Kuhn, et al., "Early detection of cancer," *Science*, vol. 375, p. eaay9040, 2022.
- [3] G. Spear, K. Lee, A. DePersia, T. Lienhoop, and P. Saha, "Updates in breast cancer screening and diagnosis," *Current Treatment Options in Oncology*, vol. 25, pp. 1451–1460, 2024.
- [4] A. M. D. Wolf, K. C. Oeffinger, T. Y. Shih, L. C. Walter, T. R. Church, E. T. H. Fontham, E. B. Elkin, R. D. Etzioni, C. E. Guerra, R. B. Perkins, et al., "Screening for lung cancer: 2023 guideline update from the American Cancer Society," *CA: A Cancer Journal for Clinicians*, vol. 74, pp. 50–81, 2024.
- [5] P. Bandi, J. Star, K. Ashad-Bishop, T. Kratzer, R. Smith, and A. Jemal, "Lung cancer screening in the US, 2022," *JAMA Internal Medicine*, vol. 184, pp. 882–891, 2024.
- [6] S. Xu, S. Murtagh, Y. Han, F. Wan, and A. T. Toriola, "Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status," *JAMA Network Open*, vol. 7, p. e2353331, 2024.
- [7] A. Jemal, E. J. Schafer, H. Sung, P. Bandi, T. Kratzer, F. Islami, and R. L. Siegel, "The burden of lung cancer in women compared with men in the US," *JAMA Oncology*, vol. 9, pp. 1727–1728, 2023.
- [8] A. P. Klein, "Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors," *Nature Reviews Gastroenterology & Hepatology*, vol. 18, pp. 493–502, 2021.
- [9] R. L. Siegel, A. N. Giaquinto, and A. Jemal, "Cancer statistics, 2024," *CA: A Cancer Journal for Clinicians*, vol. 74, pp. 12–49, 2024.
- [10] Y.-F. Wei, L. Ning, Y.-L. Xu, J. Ma, D.-R. Li, Z.-F. Feng, F.-H. Liu, Y.-Z. Li, H.-L. Xu, P. Li, et al., "Worldwide patterns and trends in ovarian cancer incidence by histological subtype: A population-based analysis from 1988 to 2017," *eClinicalMedicine*, vol. 79, p. 102983, 2025.
- [11] A. Upadhyay, V. Garg, S. Mathur, P. Singh Malik, N. Bhatla, S. Kumar, S. Khurana, and L. Kumar, "Early-stage epithelial ovarian cancer: Predictors of survival," *Gynecologic Oncology Reports*, vol. 44, p. 101083, 2022.
- [12] S. W. Fu, C. Tang, X. Tan, and S. Srivastava, "Liquid biopsy for early cancer detection: Technological revolutions and clinical dilemma," *Expert Review of Molecular Diagnostics*, vol. 24, pp. 937–955, 2024.
- [13] S. M. Batool, A. Yekula, P. Khanna, T. Hsia, A. S. Gamblin, E. Ekanayake, A. K. Escobedo, D. G. You, C. M. Castro, H. Im, et al., "The liquid biopsy consortium: Challenges and opportunities for early cancer

- detection and monitoring,” *Cell Reports Medicine*, vol. 4, p. 101198, 2023.
- [14] S. Foser, K. Maiese, S. R. Digumathy, J. A. Puig-Butille, and C. Rebhan, “Looking to the future of early detection in cancer: Liquid biopsies, imaging, and artificial intelligence,” *Clinical Chemistry*, vol. 70, pp. 27–32, 2024.
- [15] L. Ma, H. Guo, Y. Zhao, Z. Liu, C. Wang, J. Bu, T. Sun, and J. Wei, “Liquid biopsy in cancer: Current status, challenges and future prospects,” *Signal Transduction and Targeted Therapy*, vol. 9, p. 336, 2024.
- [16] S. Chakraborty, M. I. Hosen, M. Ahmed, and H. U. Shekhar, “Onco-multi-omics approach: A new frontier in cancer research,” *BioMed Research International*, vol. 2018, p. 9836256, 2018.
- [17] C. Baldini, L. Billeci, F. Sansone, R. Conte, C. Domenici, and A. Tonacci, “Electronic nose as a novel method for diagnosing cancer: A systematic review,” *Biosensors*, vol. 10, p. 84, 2020.
- [18] E. Baratella, M. Carbi, P. Minelli, A. Segalotti, B. Ruaro, F. Salton, R. Polverosi, and M. A. Cova, “Calcified lung nodules: A diagnostic challenge in clinical daily practice,” *Tomography*, vol. 11, p. 28, 2025.
- [19] R. Brahimetaj, I. Willekens, A. Massart, R. Forsyth, J. Cornelis, J. D. Mey, and B. Jansen, “Improved automated early detection of breast cancer based on high resolution 3D micro-CT microcalcification images,” *BMC Cancer*, vol. 22, p. 162, 2022.
- [20] E. O’Connor, M. Mullins, D. O’Connor, S. Phelan, and J. Bruzzi, “The relationship between ultrasound microcalcifications and psammoma bodies in thyroid tumours: A single-institution retrospective study,” *Clinical Radiology*, vol. 77, pp. e48–e54, 2022.
- [21] F. Porcelli, M. Verri, S. De Santis, A. Crescenzi, A. Bianchi, A. C. Felici, G. Sotgiu, S. Romano, and M. Orsini, “Considerations on chemical composition of psammoma bodies: Automated detection strategy by infrared microspectroscopy in ovarian and thyroid cancer tissues,” *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, vol. 298, p. 122792, 2023.
- [22] B. Cena, E. Melloul, N. Demartines, O. Dormond, and I. Labgaa, “Basic science with preclinical models to investigate and develop liquid biopsy: What are the available data and is it a fruitful approach?,” *International Journal of Molecular Sciences*, vol. 23, p. 5343, 2022.
- [23] C. Alix-Panabieres, D. Marchetti, and J. E. Lang, “Liquid biopsy: From concept to clinical application,” *Scientific Reports*, vol. 13, p. 21685, 2023.
- [24] S. Connal, J. M. Cameron, A. Sala, P. M. Brennan, D. S. Palmer, J. D. Palmer, H. Perlow, and M. J. Baker, “Liquid biopsies: The future of cancer early detection,” *Journal of Translational Medicine*, vol. 21, p. 118, 2023.
- [25] Z. Chen, C. Li, Y. Zhou, Y. Yao, J. Liu, M. Wu, and J. Su, “Liquid biopsies for cancer: From bench to clinic,” *MedComm*, vol. 4, p. e329, 2023.
- [26] B. D. Nicholson, J. Oke, P. S. Virdee, D. A. Harris, C. O’Doherty, J. E. Park, Z. Hamady, V. Sehgal, A. Millar, L. Medley, et al., “Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPHONY): A large-scale, observational cohort study,” *The Lancet Oncology*, vol. 24, pp. 733–743, 2023.
- [27] C. Luchini, N. Veronese, A. Nottegar, V. Cappelletti, M. G. Daidone, L. Smith, C. Parris, L. A. A. Brosens, M. G. Caruso, L. Cheng, et al., “Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine,” *Cancers*, vol. 11, p. 1152, 2019.